Kapitalo Investimentos Ltda Purchases 1,621 Shares of Haemonetics Co. (NYSE:HAE)

Kapitalo Investimentos Ltda increased its position in Haemonetics Co. (NYSE:HAE) by 80.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,636 shares of the medical instruments supplier’s stock after purchasing an additional 1,621 shares during the period. Kapitalo Investimentos Ltda’s holdings in Haemonetics were worth $311,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of HAE. Vanguard Group Inc. grew its holdings in shares of Haemonetics by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 5,406,309 shares of the medical instruments supplier’s stock valued at $462,293,000 after buying an additional 25,451 shares during the last quarter. Wellington Management Group LLP boosted its stake in Haemonetics by 3.2% during the 4th quarter. Wellington Management Group LLP now owns 3,268,083 shares of the medical instruments supplier’s stock valued at $279,454,000 after purchasing an additional 101,029 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Haemonetics by 7.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 826,731 shares of the medical instruments supplier’s stock worth $70,697,000 after purchasing an additional 59,670 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in shares of Haemonetics by 27.2% in the fourth quarter. Westfield Capital Management Co. LP now owns 712,061 shares of the medical instruments supplier’s stock worth $60,888,000 after purchasing an additional 152,098 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Haemonetics by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 534,694 shares of the medical instruments supplier’s stock valued at $45,722,000 after purchasing an additional 8,901 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Activity at Haemonetics

In other news, insider Stewart W. Strong sold 733 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $96.04, for a total value of $70,397.32. Following the completion of the transaction, the insider now directly owns 15,608 shares of the company’s stock, valued at $1,498,992.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Stewart W. Strong sold 686 shares of the stock in a transaction on Monday, May 20th. The stock was sold at an average price of $95.11, for a total value of $65,245.46. Following the sale, the insider now owns 18,196 shares in the company, valued at $1,730,621.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Stewart W. Strong sold 733 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $96.04, for a total value of $70,397.32. Following the transaction, the insider now owns 15,608 shares of the company’s stock, valued at $1,498,992.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,380 shares of company stock worth $2,445,816. Corporate insiders own 1.80% of the company’s stock.

Haemonetics Stock Performance

Shares of HAE traded down $0.26 during mid-day trading on Tuesday, hitting $85.33. The stock had a trading volume of 37,102 shares, compared to its average volume of 502,785. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.56 and a quick ratio of 1.50. The firm has a market cap of $4.35 billion, a P/E ratio of 37.37, a PEG ratio of 1.54 and a beta of 0.37. Haemonetics Co. has a 52 week low of $70.74 and a 52 week high of $97.97. The business has a fifty day moving average price of $88.98 and a 200-day moving average price of $83.65.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.90 EPS for the quarter, beating the consensus estimate of $0.88 by $0.02. Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. The business had revenue of $343.00 million for the quarter, compared to the consensus estimate of $329.53 million. During the same period in the prior year, the firm earned $0.77 earnings per share. The company’s revenue was up 12.7% compared to the same quarter last year. On average, equities research analysts expect that Haemonetics Co. will post 4.57 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on HAE. JMP Securities increased their price target on Haemonetics from $115.00 to $125.00 and gave the company a “market outperform” rating in a research report on Friday, May 10th. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TheStreet cut shares of Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th. Needham & Company LLC raised Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 target price for the company in a report on Wednesday, June 12th. Finally, Barrington Research lifted their price target on Haemonetics from $105.00 to $107.00 and gave the stock an “outperform” rating in a report on Friday, May 10th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Haemonetics presently has an average rating of “Moderate Buy” and a consensus target price of $109.50.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.